May 7th news, according to DL News, the governance token ARB of Ethereum Layer2 network Arbitrum has plummeted by 71% in the past year, leading to a significant drop in its DAO voting participation rate. In response to this predicament, the Arbitrum community is considering lowering the minimum voting threshold required for proposal approval from 5% to 4.5% to revitalize governance activity. This move stems from an increasingly severe governance participation crisis. Data shows that Arbitrum's governance participation has decreased by 50% over the past year, and its token price has fallen by 87% from its historical high. Community representatives pointed out that when token holders suffer significant losses, their enthusiasm for participating in governance naturally diminishes. This situation not only affects daily decision-making but may also result in quality proposals failing to pass. Some representatives support lowering the threshold as a temporary measure, but the core issue lies in the ecosystem's lack of actual value to retain token holders.
The Arbitrum community is considering lowering the minimum voting threshold required to pass proposals from 5% to 4.5%
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
